Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Phase 2 Unknown 196 enrolled Fudan University

NaSingle-groupOpen-labelTreatment

Summary

The aim of this study is to optimize the number of cycles of R-CHOP in patients with diffuse large B-cell lymphoma based on the interim results of PET/CT.

Timeline

Start: 2013-02
Primary completion: 2015-12
Completion: 2017-12

Publications

Jin J, Ji D, Xia Z, Xue K, Zhang Q, Liu Y, Cao J, Hong X, Gu JJ, Guo Y, Lv F. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial. BMC Cancer. 2022 Apr 13;22(1):403. doi: 10.1186/s12885-022-09486-4.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	750 mg/m2	Intravenous
Subject	Doxorubicin	Other / unclassified	50 mg/m2	Intravenous
Subject	Prednisone	Other / unclassified	50 mg	Oral
Subject	Rituximab	Monoclonal antibody	375 mg/m2	—
Subject	Vincristine	Small molecule	1.4 mg/m2	Intravenous

Interim PET/CT Guided Cycle Numbers of R-CHOP in DLBCL

Summary

Timeline

Publications

Drugs

Indications